204 related articles for article (PubMed ID: 24784718)
21. Exploring chromosomal abnormalities and genetic changes in uterine smooth muscle tumors.
Liegl-Atzwanger B; Heitzer E; Flicker K; Müller S; Ulz P; Saglam O; Tavassoli F; Devouassoux-Shisheboran M; Geigl J; Moinfar F
Mod Pathol; 2016 Oct; 29(10):1262-77. PubMed ID: 27363490
[TBL] [Abstract][Full Text] [Related]
22. Chromosome aberrations in uterine smooth muscle tumors: potential diagnostic relevance of cytogenetic instability.
Fletcher JA; Morton CC; Pavelka K; Lage JM
Cancer Res; 1990 Jul; 50(13):4092-7. PubMed ID: 2354458
[TBL] [Abstract][Full Text] [Related]
23. MRI findings in-between leiomyoma and leiomyosarcoma: a Rad-Path correlation of degenerated leiomyomas and variants.
Bura V; Pintican RM; David RE; Addley HC; Smith J; Jimenez-Linan M; Lee J; Freeman S; Georgiu C
Br J Radiol; 2021 Sep; 94(1125):20210283. PubMed ID: 34289327
[TBL] [Abstract][Full Text] [Related]
24. Smooth muscle neoplasms of the urinary bladder: a clinicopathologic study of 51 cases.
Lee TK; Miyamoto H; Osunkoya AO; Guo CC; Weiss SW; Epstein JI
Am J Surg Pathol; 2010 Apr; 34(4):502-9. PubMed ID: 20154594
[TBL] [Abstract][Full Text] [Related]
25. Mast cells in smooth muscle tumors of the uterus.
Orii A; Mori A; Zhai YL; Toki T; Nikaido T; Fujii S
Int J Gynecol Pathol; 1998 Oct; 17(4):336-42. PubMed ID: 9785134
[TBL] [Abstract][Full Text] [Related]
26. Explorative Investigation of Whole-Lesion Histogram MRI Metrics for Differentiating Uterine Leiomyomas and Leiomyosarcomas.
Gerges L; Popiolek D; Rosenkrantz AB
AJR Am J Roentgenol; 2018 May; 210(5):1172-1177. PubMed ID: 29547053
[TBL] [Abstract][Full Text] [Related]
27. Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors.
Ünver NU; Acikalin MF; Öner Ü; Ciftci E; Ozalp SS; Colak E
Arch Gynecol Obstet; 2011 Aug; 284(2):483-90. PubMed ID: 20878171
[TBL] [Abstract][Full Text] [Related]
28. [Uterine smooth muscle tumors: retrospective epidemiological and pathological study of 2760 cases].
Rammeh-Rommani S; Mokni M; Stita W; Trabelsi A; Hamissa S; Sriha B; Tahar-Yacoubi M; Korbi S
J Gynecol Obstet Biol Reprod (Paris); 2005 Oct; 34(6):568-71. PubMed ID: 16208199
[TBL] [Abstract][Full Text] [Related]
29. Immunoexpression of p53 in cutaneous and subcutaneous leiomyosarcomas.
Fernandez-Flores A; Monteagudo C
Ann Diagn Pathol; 2016 Oct; 24():25-9. PubMed ID: 27649950
[TBL] [Abstract][Full Text] [Related]
30. Potential diagnostic biomarkers: differential expression of LMP2/β1i and cyclin B1 in human uterine leiomyosarcoma.
Hayashi T; Horiuchi A; Sano K; Hiraoka N; Ichimura T; Sudo T; Ishiko O; Yaegashi N; Aburatani H; Konishi I
Tumori; 2014; 100(4):99e-106e. PubMed ID: 25296613
[TBL] [Abstract][Full Text] [Related]
31. Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyoma-like areas.
Mittal KR; Chen F; Wei JJ; Rijhvani K; Kurvathi R; Streck D; Dermody J; Toruner GA
Mod Pathol; 2009 Oct; 22(10):1303-11. PubMed ID: 19633649
[TBL] [Abstract][Full Text] [Related]
32. Oncofetal protein IMP3: a useful diagnostic biomarker for leiomyosarcoma.
Cornejo K; Shi M; Jiang Z
Hum Pathol; 2012 Oct; 43(10):1567-72. PubMed ID: 22497850
[TBL] [Abstract][Full Text] [Related]
33. The selected biomarker analysis in 5 types of uterine smooth muscle tumors.
Zhang Q; Kanis MJ; Ubago J; Liu D; Scholtens DM; Strohl AE; Lurain JR; Shahabi S; Kong B; Wei JJ
Hum Pathol; 2018 Jun; 76():17-27. PubMed ID: 29258902
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic value of progesterone receptor and p53 expression in uterine smooth muscle tumors.
Hewedi IH; Radwan NA; Shash LS
Diagn Pathol; 2012 Jan; 7():1. PubMed ID: 22217299
[TBL] [Abstract][Full Text] [Related]
35. Expression of H1.5 and PLZF in granulosa cell tumors and normal ovarian tissues: a short report.
Momeni M; Kalir T; Farag S; Chuang L; Fishman D; Burstein DE
Cell Oncol (Dordr); 2014 Jun; 37(3):229-34. PubMed ID: 25023763
[TBL] [Abstract][Full Text] [Related]
36. Pathologic considerations of uterine smooth muscle tumors.
Prayson RA; Hart WR
Obstet Gynecol Clin North Am; 1995 Dec; 22(4):637-57. PubMed ID: 8786875
[TBL] [Abstract][Full Text] [Related]
37. Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization.
Packenham JP; du Manoir S; Schrock E; Risinger JI; Dixon D; Denz DN; Evans JA; Berchuck A; Barrett JC; Devereux TR; Ried T
Mol Carcinog; 1997 Aug; 19(4):273-9. PubMed ID: 9290705
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors.
Chen L; Yang B
Int J Gynecol Pathol; 2008 Jul; 27(3):326-32. PubMed ID: 18580309
[TBL] [Abstract][Full Text] [Related]
39. Role of the Immunohistochemical ZEB1 Expression in Uterine Mesenchymal Neoplasms.
Çelik M; Çelik ZE
Int J Surg Pathol; 2022 Aug; 30(5):520-527. PubMed ID: 34994578
[TBL] [Abstract][Full Text] [Related]
40. Uterine sarcomas versus leiomyomas: gray-scale and Doppler sonographic findings.
Aviram R; Ochshorn Y; Markovitch O; Fishman A; Cohen I; Altaras MM; Tepper R
J Clin Ultrasound; 2005 Jan; 33(1):10-3. PubMed ID: 15690441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
